ClinicalTrials.gg
CompletedNCT00694135Updated Aug 31, 2010

Safety and Efficacy Study of Iontophoresis and Dexamethasone Phosphate to Treat Anterior Uveitis

A Phase 2 interventional study of EGP-437 1.6 mA-min at 0.4 with EyeGate® II System and EGP-437 4.8 mA-min at 1.2 mA with EyeGate® II System in Uveitis, Anterior, sponsored by Eyegate Pharmaceuticals, Inc.. Completed at 19 sites in 2 countries. Open to participants aged 12 Years to 85 Years. Per ClinicalTrials.gov, last updated 2010-08-31.

Sponsored by Eyegate Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
12 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 30 studies in Uveitis, Anterior with a site in United States — 5 open to participants now, 6 under way, none of them phase 3. Uveitis, Anterior · United States.

Enrollment
14th of 27
40 · median 40
Started
2008
the only one that year
Phase 2
6 of 30
1 open now
Registered
5th of 30
by date
Lead sponsor
3 of 30
Eyegate Pharmaceuticals, Inc.

Among the 30 studies in Uveitis, Anterior with a site in United States, this one is the 14th largest by enrollment of the 27 interventional ones that give a count, is the only one that started in 2008, is one of 6 in phase 2, and was the 5th registered.

Uveitis, Anterior

56 studies on the registry are indexed under Uveitis, Anterior; 9 are open to participants now.

Browse Uveitis, Anterior studies →

Open to participants now

5 of the 30 studies in Uveitis, Anterior with a site in United States are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 4 Uveitis, Anterior studies recruiting now, 2 set no upper age limit and 1 stops at 75 or younger; 2 take children under 18; 2 take healthy volunteers.

This study: 12 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Uveitis, Anterior with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to define a safe and effective dose of iontophoretic delivery of dexamethasone phosphate ophthalmic solution using the EyeGate® II Drug Delivery System in patients with non-infectious anterior segment uveitis.

Read the detailed description

This is a randomized, double-masked, parallel group, dose-comparison, exploratory study of four doses of iontophoretic delivery of dexamethasone phosphate ophthalmic solution in patients with non-infectious anterior segment uveitis. The current study will evaluate the safety, tolerability, and efficacy of this technology at the four dose levels to determine a safe effective dose appropriate for future trials.

03

Conditions studied

  • Uveitis, Anterior

Browse trials for

Keywords

  • Iontophoresis
  • Non-Infectious Acute Anterior Segment Uveitis
  • Ophthalmology
04

Who can participate

Ages eligible
12 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Non-infectious anterior uveitis

Exclusion criteria

Exclusion Criteria:

  • Uveitis of infectious etiology
  • Previous anterior uveitis episode ≤ 4 weeks prior to baseline
  • Intraocular pressure (IOP) ≥ 25 mmHg at baseline, a history of glaucoma, and/or patients who require ocular anti-hypertensive medications
  • Topical treatment in either eye \< 48 hours prior to baseline
  • Oral corticosteroid or intraorbital corticosteroid treatment in either eye \< 2 weeks prior to baseline
  • Active intermediate or posterior uveitis
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
40 participants (actual)

Study arms

  • Active comparator
    EGP-437 1.6 mA-min at 0.4 mA

    Ocular iontophoresis with EGP 437 1.6 mA-min at 0.4 mA

    Drug: EGP-437 1.6 mA-min at 0.4 with EyeGate® II System

  • Active comparator
    EGP-437 4.8 mA-min at 1.2 mA

    Ocular iontophoresis with EGP-437 4.8 mA-min at 1.2 mA

    Drug: EGP-437 4.8 mA-min at 1.2 mA with EyeGate® II System

  • Active comparator
    EGP-437 10.0 mA-min at 2.5 mA

    Ocular iontophoresis with EGP-437 10.0 mA-min at 2.5 mA

    Drug: EGP-437 10.0 mA-min at 2.5 mA with EyeGate® II System

  • Active comparator
    EGP-437 14.0 mA-min at 3.5 mA

    Ocular iontophoresis with EGP-437 14.0 mA-min at 3.5 mA

    Drug: EGP-437 14.0 mA-min at 3.5 mA with EyeGate® II System

Interventions

  • DrugEGP-437 1.6 mA-min at 0.4 with EyeGate® II System

    Drug page: Dexamethasone phosphate

    Ocular Iontophoresis with EGP-437 1.6 mA-min at 0.4 mA delivered via EyeGate® II Drug Delivery System

    Also known as: Dexamethasone Phosphate Ophthalmic Solution

  • DrugEGP-437 4.8 mA-min at 1.2 mA with EyeGate® II System

    Drug page: Dexamethasone phosphate

    Ocular Iontophoresis with EGP-437 4.8 mA-min at 1.2 mA delivered via EyeGate® II Drug Delivery System

    Also known as: Dexamethasone Phosphate Ophthalmic Solution

  • DrugEGP-437 10.0 mA-min at 2.5 mA with EyeGate® II System

    Drug page: Dexamethasone phosphate

    Ocular Iontophoresis with EGP-437 10.0 mA-min at 2.5 mA delivered via EyeGate® II Drug Delivery System

    Also known as: Dexamethasone Phosphate Ophthalmic Solution

  • DrugEGP-437 14.0 mA-min at 3.5 mA with EyeGate® II System

    Drug page: Dexamethasone phosphate

    Ocular Iontophoresis with EGP-437 14.0 mA-min at 3.5 mA delivered via EyeGate® II Drug Delivery System

    Also known as: Dexamethasone Phosphate Ophthalmic Solution

06

What researchers measure

Primary outcomes

  1. Proportion of subjects with an ACC score of zero at Days 14 and 28

    Proportion of subjects with an anterior chamber cell (ACC) score of zero at Days 14 and 28

    Time frame: Prospective study, subjects followed for 28 days

Secondary outcomes

  1. Time to ACC score of zero

    Time to anterior chamber cell score of zero

    Time frame: Prospective study, subjects followed for 28 days

  2. Proportion of subjects with a reduction of one full ACC score or more from baseline at Day 28

    Proportion of subjects with a reduction of one full anterior chamber cell score or more (≥ 0.5 decrease) from baseline at Day 28

    Time frame: Prospective study, subjects followed for 28 days

  3. Change from baseline in ACC score at Day 28

    Change from baseline in anterior chamber cell score at Day 28

    Time frame: Prospective study, subjects followed for 28 days

  4. Treatment emergent adverse events

    Treatment emergent adverse events

    Time frame: Prospective study, subjects followed for 28 days

07

Study locations

19 sites
  • University of Miami
    Miami, Florida 33136, United States
  • Emory Eye Center
    Atlanta, Georgia 30322, United States
  • Ophthalmic Consultants of Boston
    Boston, Massachusetts 02114, United States
  • Massachusetts Eye Research and Surgery Institution
    Cambridge, Massachusetts 02142, United States
  • Comprehensive Eye Care Ltd.
    Washington, Missouri 63090, United States
  • New York Eye & Ear Infirmary
    New York, New York 10003, United States
  • Cleveland Eye Clinic
    Cleveland, Ohio 44195, United States
  • Oregon Health Services University
    Portland, Oregon 97239, United States
  • Pennsylvania College of Optometry
    Elkins Park, Pennsylvania 19027, United States
  • Scheie Eye Institue
    Philadelphia, Pennsylvania 19104, United States
  • Southern College of Optometry
    Memphis, Tennessee 38104, United States
  • Texas Retina Associates
    Dallas, Texas 75231, United States
  • Virginia Eye Consultants
    Norfolk, Virginia 23502, United States
  • St. Johns Medical College and Hospital
    Bangalore, Karnataka 560 037, India
  • Vittala International Institute of Ophthalmology
    Bangalore, Karnataka 560 037, India
  • Narayana Nethralaya
    Bangalore, Karnataka 560010, India
  • M. M. Joshi Eye Institute
    Hubli, Karnataka 580 021, India
  • Kasturba Medical College and Hospital
    Manipal, Karnataka 576104, India
  • Christian Medical College
    Vellore, Tamil Nadu 632011, India
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2008, a primary completion of Jul 2009 and a completion of Aug 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 5, 2008
First posted
Jun 10, 2008
Start
Jun 2008
Primary completionActual
Jul 2009
CompletionActual
Aug 2009
Results delay requested
Aug 20, 2010
Last update
Aug 31, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 31, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00694135
Lead sponsor
Eyegate Pharmaceuticals, Inc.
First posted
Jun 10, 2008
Start date
Jun 2008
Primary completion
Jul 2009
Completion
Aug 2009
Last update
Aug 31, 2010

Study contacts

C. Stephen Foster, MD
principal investigator · Massachusetts Eye Research and Surgery Institution
Michael Raizman, MD
principal investigator · Ophthalmic Consultants of Boston

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexamethasone phosphate

Start the discussion